Prescribing information



Meeting date: 5th July 2021

This webinar took place originally on the 5th of July. On the 12th of July, KESIMPTA (ofatumumab) was accepted by the SMC.1 

Speakers: Dr David Paling, Consultant Neurologist, Sheffield Teaching Hospitals; Joela Mathews, Lead Neuroscience Pharmacist for Barts Health NHS Trust.

In this webinar, consultant neurologist Dr David Paling and specialist pharmacist Joela Mathews discuss the treatment of MS patients outside of the hospital setting. Considering the latest data, they explore how integrating KESIMPTA (ofatumumab) into local patient pathways could benefit both patients and healthcare services.

This meeting was organised and funded by Novartis Pharmaceuticals UK Ltd. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.


Service impact case study

Watch Joela Mathews explore the variations in care and capacity issues in MS treatment, and how home infusion can improve the patient pathway and reduce healthcare costs.


Service impact example

See Joela Mathews discuss the patient and healthcare pathways in MS, and how KESIMPTA can help generate efficiencies by moving care closer to home.


KESIMPTA demonstration pen injection

Watch Dr David Paling demonstrate how easy it is to use the KESIMPTA Sensoready® injection pen, and how it can benefit patients.


Prescribing information for KESIMPTA®▼ (ofatumumab) and adverse event reporting details can be found here.

Prescribing information for MAYZENT▼ (siponimod) and adverse event reporting details can be found here.

Prescribing information for GILENYA▼ (fingolimod) and adverse event reporting details can be found here

MS, multiple sclerosis; SMC, Scottish medicines consortium.


  1. Scottish Medicines Consortium (2021). Advice following a full submission: ofatumumab (Kesimpta®) is accepted for restricted use within NHSScotland. Available at: [Accessed July 2021].
Rate this content: 
Average: 5 (1 vote)
UK | March 2022 | 197360

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]